Health Care·NASDAQ·All covered stocks

Biogen Inc. (NASDAQ: BIIB) Stock News & Analysis

Biogen Inc. (NASDAQ: BIIB) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 4 articles on BIIB since April 29, 2026, most recently "Biogen Acquires RayThera for Up to $1B and Wins FDA Breakthrough Tag for Salanersen" on Monday, June 29, 2026. Coverage to date spans Health Care and Earnings Report, tracking BIIB's earnings, analyst activity, and material corporate events. New coverage is added each trading day.

Price

$210.73

Today

-0.83%

Mkt Cap

$31.1B

P/E

37.8x

52W High

$225.80

52W Low

$135.39

Data via Finnhub · refreshes hourly · not financial advice

BIIB Coverage -- 4 Articles

Health Care·Monday, June 29, 2026

Biogen Acquires RayThera for Up to $1B and Wins FDA Breakthrough Tag for Salanersen

Biogen just bought RayThera for up to $1B and secured an FDA Breakthrough Therapy designation for Salanersen, stacking two immunology pipeline wins in one session.

3 min readRead article

Important Legal Disclaimer

This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.

Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.

Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.